169 related articles for article (PubMed ID: 3140887)
41. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
42. In vitro effects of an acyltripeptide, FK565, on NK-cell activity, LAK-cell generation and cytokine production by human mononuclear cells.
Wang YL; Whiteside TL; Friberg D; Herberman RB
Immunopharmacology; 1989; 17(3):175-85. PubMed ID: 2504680
[TBL] [Abstract][Full Text] [Related]
43. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
44. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
Griffiths SD; Cawley JC
Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
[TBL] [Abstract][Full Text] [Related]
45. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
Reiter Z
J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
[TBL] [Abstract][Full Text] [Related]
46. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
47. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
48. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
49. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.
Gottlieb DJ; Prentice HG; Mehta AB; Galazka AR; Heslop HE; Hoffbrand AV; Brenner MK
Br J Haematol; 1990 Aug; 75(4):499-505. PubMed ID: 2119792
[TBL] [Abstract][Full Text] [Related]
50. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
Di Raimondo F; LaPushin R; Hersh EM
Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
[TBL] [Abstract][Full Text] [Related]
51. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
Yoneda K; Osaki T; Yamamoto T; Ueta E
Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
[TBL] [Abstract][Full Text] [Related]
52. Dual role of TNF-alpha in NK/LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis.
Fortis C; Biswas P; Soldini L; Veglia F; Careddu AM; Delfanti F; Mantelli B; Murone M; Lazzarin A; Poli G
Eur J Immunol; 1999 Nov; 29(11):3654-62. PubMed ID: 10556821
[TBL] [Abstract][Full Text] [Related]
53. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
54. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
Anderson TM; Ibayashi Y; Holmes EC; Golub SH
Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
[TBL] [Abstract][Full Text] [Related]
55. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer.
Mueller EA; Anderer FA
Cancer Immunol Immunother; 1990; 32(4):221-7. PubMed ID: 2124513
[TBL] [Abstract][Full Text] [Related]
56. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
57. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
58. Immunoregulatory properties of ISG15, an interferon-induced cytokine.
D'Cunha J; Knight E; Haas AL; Truitt RL; Borden EC
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):211-5. PubMed ID: 8552607
[TBL] [Abstract][Full Text] [Related]
59. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
[TBL] [Abstract][Full Text] [Related]
60. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
